Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Atox Bio
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
The Israeli biotech is eagerly awaiting Phase III data on its therapy for necrotizing soft tissue infections before the end of 2019.
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
- Large Molecule